Sobi presents today at J.P. Morgan Annual Healthcare Conference
(Thomson Reuters ONE) -
Sobi President and CEO Geoffrey McDonough today made a company presentation at
the J.P. Morgan Annual Healthcare Conference in San Francisco.
In his presentation Dr McDonough highlighted the newly implemented operational
structure to focus on growth in three business lines: Core Products including
Kineret® and Orfadin®, Specialty Distribution Portfolio focused mainly in the
Nordic, Baltic, and CEE regions, and manufacturing for Refacto AF® in
partnership with Pfizer. He emphasized the company's overall goals to improve
gross margin and cash flow, and to successfully commercialize the company's
three late stage projects. The late stage projects include Kiobrina®, an enzyme
replacement therapy to improve growth in preterm infants, and long-acting
recombinant coagulation factors 8 and 9 for hemophilia A and B being developed
in collaboration with Biogen Idec.
Dr McDonough also commented on the new distribution agreement with the Italian
company Gentium regarding Defibrotide in the Nordic and Baltic regions announced
yesterday by Gentium. Defibrotide has the potential to become the first drug
approved for the prevention and treatment of hepatic veno-occlusive disease
(VOD) a serious and potentially fatal complication of hematopoietic stem-cell
transplantation (HSCT).
An audiocast of the presentation is available at www.sobi.com.
For further information, please contact:
Åsa Stenqvist, Head of Communications and Investor Relations
Tel.: +46 8 697 21 88
Swedish Orphan Biovitrum (Sobi)
Sobi is a leading integrated biopharmaceutical company dedicated to bringing
innovative therapies and services to improve the health of rare disease patients
and their families. The product portfolio comprises about 60 marketed products
as well as projects in the late clinical phase. Key therapeutic areas are
Inflammation and Genetics & Metabolism. In 2010 Sobi had revenues of SEK 1.9
billion and around 500 employees. The share (STO: SOBI) is listed on OMX NASDAQ
Stockholm. More information is available atwww.sobi.com.
JPM Press Release in pdf format:
http://hugin.info/134557/R/1576550/491363.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
[HUG#1576550]
Unternehmensinformation / Kurzprofil:
Datum: 10.01.2012 - 18:02 Uhr
Sprache: Deutsch
News-ID 102879
Anzahl Zeichen: 2976
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 175 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sobi presents today at J.P. Morgan Annual Healthcare Conference"
steht unter der journalistisch-redaktionellen Verantwortung von
Swedish Orphan Biovitrum AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
